Provided by Tiger Trade Technology Pte. Ltd.

Warrior Met Coal LLC

94.38
-2.3400-2.42%
Post-market: 94.37-0.0100-0.01%18:31 EDT
Volume:452.26K
Turnover:43.02M
Market Cap:4.96B
PE:22.69
High:98.02
Open:95.94
Low:86.95
Close:96.72
52wk High:110.39
52wk Low:54.66
Shares:52.57M
Float Shares:51.47M
Volume Ratio:0.64
T/O Rate:0.88%
Dividend:0.32
Dividend Rate:0.34%
EPS(TTM):4.16
EPS(LYR):1.08
ROE:10.04%
ROA:5.17%
PB:2.17
PE(LYR):87.39

Loading ...

SQM Stock And 2 Global Exporters For Investors Looking Beyond Tech

Simply Wall St.
·
Jun 24

Warrior Met Coal’s (HCC) Insider Sales Amid Rich Valuation: What Do They Signal About Risk‑Reward?

Simply Wall St.
·
Jun 24

Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson

GlobeNewswire
·
Jun 22

Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026

GlobeNewswire
·
Jun 17

Warrior Met Coal Is Maintained at Buy by B. Riley Securities

Dow Jones
·
Jun 11

Warrior Met Coal Inc : B. Riley Raises Target Price to $123 From $117

THOMSON REUTERS
·
Jun 10

B. Riley Raises Price Target on Warrior Met Coal to $123 From $117, Keeps Buy Rating

MT Newswires Live
·
Jun 10

Warrior Met Coal Chief Administrative Officer Kelli K. Gant sells 20,000 shares for $2.2 million

Reuters
·
Jun 05

RBC Capital Reaffirms Their Hold Rating on Warrior Met Coal (HCC)

TIPRANKS
·
Jun 04

ABBISKO-B Presents Innovative Modeling Framework for ABSK-011 in HCC at PAGE Conference

Stock News
·
Jun 04

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

Dow Jones
·
May 28

Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC

GlobeNewswire
·
May 27

Assessing Warrior Met Coal (HCC) Valuation After Recent Share Price Softness And Blue Creek Growth Plans

Simply Wall St.
·
May 27

Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma

GlobeNewswire
·
May 21

Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market

GlobeNewswire
·
May 18

A Look At Warrior Met Coal (HCC) Valuation After Early Blue Creek Spend And Strong Q1 Results

Simply Wall St.
·
May 18

Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy

GlobeNewswire
·
May 13

Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment

GlobeNewswire
·
May 13

A Look At Warrior Met Coal (HCC) Valuation As Long Term Returns Outpace Recent Share Price Moves

Simply Wall St.
·
May 09

Is It Time To Reassess Warrior Met Coal (HCC) After Its Recent Share Price Pullback

Simply Wall St.
·
May 06